Dietary Management of Feline Chronic Renal Failure: Where are We Now? In What Direction are We Headed?

2000 ◽  
Vol 2 (2) ◽  
pp. 75-82 ◽  
Author(s):  
D J Polzin ◽  
C A Osborne ◽  
S Ross ◽  
F Jacob
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Clinical Signs ◽  
Dietary Therapy ◽  
Dietary Management ◽  
Dietary Intakes ◽  
Normal Range ◽  
Limited Ability ◽  
Diet Formulation ◽  
Therapeutic Value

Dietary modification is of primary importance in managing cats with chronic renal failure. Diets designed for cats with chronic renal failure are typically formulated to be pH neutral and contain reduced quantities of protein, phosphorus and sodium and an increased quantity of potassium. These changes in diet formulation are designed to ameliorate clinical signs of renal failure by adapting dietary intakes to meet the limited ability of failing kidneys to adapt to the normal range of dietary intakes. Important recent clinical trials support the therapeutic value of dietary therapy in cats with chronic renal failure.

Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma

1992 ◽  
Vol 83 (2) ◽  
pp. 205-211 ◽  
Author(s):  
Toraichi Mouri ◽  
Masahiko Sone ◽  
Kazuhiro Takahashi ◽  
Keiichi Itoi ◽  
Kazuhito Totsune ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Neuropeptide Y ◽  
Healthy Adult ◽  
Plasma Samples ◽  
Normal Range ◽  
Maintenance Haemodialysis ◽  
Upper Limits ◽  
Highly Sensitive ◽  
Plasma Marker

1. We investigated the usefulness of neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma using a simple and highly sensitive r.i.a. for human neuropeptide Y. 2. Plasma immunoreactive neuropeptide Y concentrations were measured without extraction in plasma samples (100 μl) from patients with various diseases. 3. The plasma immunoreactive neuropeptide Y concentration in patients with phaeochromocytoma (172.3 ± 132.4 pmol/l, mean ± sd, n = 23) was significantly higher than that in healthy adult subjects (40.1 ± 10.1 pmol/l, n = 40, P<0.0001). The plasma immunoreactive neuropeptide Y concentrations in patients with ganglioneuroblastoma (590.7 ± 563.6 pmol/l, n = 6) and patients with neuroblastoma (566.9 ± 524.4 pmol/l, n = 15) were significantly higher than those in control children (1–9 years old, 82.2 ± 39.9 pmol/l, n = 72, P<0.0001). 4. The plasma immunoreactive neuropeptide Y concentration in patients with essential hypertension (34.0 ± 3.7 pmol/l, n = 18) was within the normal range, but in patients with chronic renal failure undergoing maintenance haemodialysis (192.1 ± 68.0 pmol/l, n = 25) and in non-dialysed patients with chronic renal failure (85.1 ± 23.1 pmol/l, n = 7) it was significantly higher than that in healthy adult subjects (P<0.0001). 5. Eighty-seven per cent of the patients with phaeochromocytoma, 67% of the patients with ganglioneuroblastoma and 80% of the patients with neuroblastoma showed plasma immunoreactive neuropeptide Y concentrations higher than the upper limits in the control subjects [62 pmol/l (adult) and 160 pmol/l (children)]. 6. These results suggest that neuropeptide Y is a useful plasma marker for these tumours in addition to other factors unless the patients have renal failure.

scholarly journals Polymorphonuclear function in naturally occurring renal failure in dogs

2009 ◽  
Vol 54 (No. 5) ◽  
pp. 236-243 ◽  
Author(s):  
S. Kralova ◽  
L. Leva ◽  
M. Toman
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Clinical Signs ◽  
Human Medicine ◽  
Strong Positive Correlation ◽  
Significant Elevation ◽  
Naturally Occurring ◽  
Main Effect ◽  
Healthy Control ◽  
Leukocyte Counts

Chronic renal failure causes immunosuppression in people and is thought to be one of the causes of non-infectious secondary immunosuppression in dogs. The purpose of this study was to evaluate changes in counts and activity of polymorphonuclears in dogs with chronic renal failure in various stages. Haematological, biochemical examinations and examination of non-specific immune response cells (total and differential leukocyte counts, phagocytosis of methacrylate particles, chemiluminescence test, and level of lysozyme) were performed in blood samples obtained from these dogs. Neutrophilia, lymphopoenia and a decreased number of eosinophils in comparison with healthy control were the main findings in groups with clinical signs. We found the statistically highly significant elevation of lysozyme level; it was in a strong positive correlation with the level of urea, creatinine and phosphorus. We did not find any statistically significant changes in phagocytosis process and other serological factors. In conclusion, despite the reports from human medicine, chronic renal failure in dogs does not alter phagocytosis. From this aspect, the elevation of lysozyme level is the main effect of uraemia.

Inhibitors of the Fibrinolytic Enzyme System in Renal Disease

1970 ◽  
Vol 39 (5) ◽  
pp. 549-557 ◽  
Author(s):  
N. B. Bennett ◽  
D. Ogston
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Damage ◽  
Enzyme System ◽  
Normal Subjects ◽  
Plasminogen Activation ◽  
Significant Elevation ◽  
Normal Range ◽  
Marked Inhibition ◽  
Serum Inhibitor

1. Levels of serum inhibitor of plasminogen activation, anti-plasmin and plasminogen activator were measured in normal subjects and patients with active glomerulonephritis and chronic renal failure. 2. Patients with active glomerulonephritis all had grossly elevated levels of serum inhibitor of plasminogen activation and significant elevation of anti-plasmin. The majority of activator levels lay at the lower end of the normal range. 3. Patients with chronic renal failure had significantly elevated levels of serum inhibitor of plasminogen activation and anti-plasmin, but the changes were less marked than in those with active glomerulonephritis. Activator levels were consistently reduced. 4. The marked inhibition of fibrinolysis in active glomerulonephritis may be a factor in the persistence of glomerular fibrin and ultimately in perpetuation of renal damage. The changes in the fibrinolytic system in chronic renal failure may determine the development of the serosal exudates characteristic of that condition.

scholarly journals Glutamate concentration in plasma, erythrocyte and muscle in relation to plasma levels of insulin-like growth factor (IGF)-I, IGF binding protein-1 and insulin in patients on haemodialysis

1998 ◽  
Vol 156 (3) ◽  
pp. 519-527 ◽  
Author(s):  
JC Divino Filho ◽  
SJ Hazel ◽  
P Furst ◽  
J Bergstrom ◽  
K Hall
Keyword(s):  
Renal Failure ◽  
Growth Factor ◽  
Plasma Levels ◽  
Glutamate Uptake ◽  
Binding Protein ◽  
Clinical Signs ◽  
Insulin Like Growth Factor ◽  
Normal Range ◽  
Insulin Levels ◽  
Igf I

Elevated insulin-like growth factor binding protein (IGFBP) levels, including IGFBP-1, occur in renal failure, and may contribute towards reduced IGF bioactivity in uraemia. The reduced IGF bioactivity may, in turn, contribute towards the disturbances in protein metabolism present in renal failure. In this study, the relationships between intra- and extracellular amino acid (AA) levels and IGF-I and/or IGFBP-1 levels were studied in 30 adult patients (aged 24-70 years) on haemodialysis who had no clinical signs of malnutrition. Blood samples (n = 30) and muscle biopsies (n = 13) were collected for determination of free AA in erythrocytes (RBC), plasma and muscle by reverse-phase HPLC while IGFBP-1, IGF-I and insulin plasma levels were determined by radioimmunoassay The patients on haemodialysis had elevated glutamate concentrations in RBC and plasma compared with healthy controls (524 +/- 26 vs 448 +/- 17 mumol/l, P < 0.05 and 45 +/- 4 vs 32 +/- 4 mumol/l, P < 0.01 respectively), although glutamate levels in muscle were within the normal range. The mean IGF-I level was slightly increased (s.d. score +0.74 +/- 0.30) but insulin levels were within the normal range. IGFBP-1 levels, which were inversely correlated to insulin (r = -0.40, P < 0.02), were elevated threefold compared with controls. No plasma AA level displayed a significant correlation with IGF-I, IGFBP-1 or insulin levels. However, glutamate concentrations in RBC were positively correlated to IGFBP-1 (r = 0.51, P < 0.01) and inversely correlated to IGF-I (r = -0.46. P < 0.01), although unrelated to insulin. Muscle glutamate, which was inversely related to RBC glutamate, displayed an opposite pattern with an inverse relation to IGFBP-1 levels (r = - 0.73, P < 0.01) and a positive correlation to IGF-I levels (r = 0.64, P < 0.02). Glutamate was the only AA to display an inverse correlation between RBC and muscle (r = -0.65, P < 0.02, n = 12). These findings lead us to propose that, in uraemia, the elevated IGFBP-I levels, which reduce the bioavailability of IGFs, are linked to glutamate uptake in muscle, resulting in accumulation of RBC glutamate. Whether there is a causal relationship or the correlation is due to some common regulator is not clarified in the present study.

scholarly journals Dietary Management of Chronic Renal Failure. The Effects of Seminar.

1998 ◽  
Vol 47 (2) ◽  
pp. 129-136
Author(s):  
Shigemi NAKAMURA ◽  
Chiyo YAMADA ◽  
Yuko HORI ◽  
Etsuko NISHIKAWA ◽  
Mari KONUMA ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Dietary Management

Dietary Management in the Patient with Chronic Renal Failure

1997 ◽  
Vol 97 (9) ◽  
pp. 16B
Author(s):  
Lori W. Turner ◽  
Patricia Faile ◽  
Min Qi Wang ◽  
Qiang Fu
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Dietary Management
Sign in / Sign up

Export Citation Format

Share Document